Literature DB >> 2473298

Autoradiographical localization of binding sites for porcine [125I]endothelin-1 in humans, pigs, and rats: functional relevance in humans.

A P Davenport1, D J Nunez, J A Hall, A J Kaumann, M J Brown.   

Abstract

Endothelin-1 (ET-1) is a recently discovered 21 amino acid peptide with potent vasoconstrictor properties. So far, its expression has been found only in porcine aorta, whereas its putative role as the endothelium-derived constricting factor (EDCF) would require it to be expressed and active in most vascular beds. We have used quantitative receptor autoradiography on pig, rat, and some human tissues to determine the distribution and localization of specific binding sites for ET-1. In some cases where binding sites were found, studies were performed to determine whether these are likely to be functional receptors. Binding sites for ET-1 have been found in heart (nerves greater than atria greater than ventricle greater than coronary arteries), kidney (glomeruli greater than papilla), adrenal (zona glomerulosa greater than medulla), cerebellum, spinal cord, gut, spleen, and lung. The binding of [125I]ET-1 was displaced at all these sites by unlabeled ET-1 but not by nitrendipine, apamin, and other vasoconstrictor peptides. ET-1 contracted strips of human coronary artery at an EC50 of 15 nM, with a maximal contraction 130% that of K+. A positive inotropic effect was found in strips of human atria (EC50 = 1 nM), which was not blocked by alpha- or beta-blockade. The widespread distribution of its binding sites suggests a more extensive role than control of vascular tone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473298     DOI: 10.1097/00005344-198900135-00045

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  35 in total

1.  Endothelin regulation of neuropeptide release from nerve endings of the posterior pituitary.

Authors:  M F Ritz; E L Stuenkel; G Dayanithi; R Jones; J J Nordmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

2.  Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart.

Authors:  P Molenaar; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

Review 3.  Endothelium-dependent vascular responses. Mediators and mechanisms.

Authors:  B M Brenner; J L Troy; B J Ballermann
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

4.  Endothelin-1 mRNA expression in the rat kidney.

Authors:  D J Nunez; E A Taylor; V M Oh; J P Schofield; M J Brown
Journal:  Biochem J       Date:  1991-05-01       Impact factor: 3.857

5.  Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor.

Authors:  H Y Lin; E H Kaji; G K Winkel; H E Ives; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

6.  [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

Authors:  A P Davenport; R E Kuc; S L Hoskins; F E Karet; F Fitzgerald
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 7.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

8.  Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1.

Authors:  Katherine E Wiley; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

9.  ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.

Authors:  J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

10.  Neonatal endothelin-1 concentrations in term infants.

Authors:  P D Macdonald; R D Paton; R W Logan
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-05       Impact factor: 5.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.